TY  - JOUR
AU  - Smith, Matthew R
AU  - Saad, Fred
AU  - Chowdhury, Simon
AU  - Oudard, Stéphane
AU  - Hadaschik, Boris A
AU  - Graff, Julie N
AU  - Olmos, David
AU  - Mainwaring, Paul N
AU  - Lee, Ji Youl
AU  - Uemura, Hiroji
AU  - De Porre, Peter
AU  - Smith, Andressa A
AU  - Brookman-May, Sabine D
AU  - Li, Susan
AU  - Zhang, Ke
AU  - Rooney, Brendan
AU  - Lopez-Gitlitz, Angela
AU  - Small, Eric J
PY  - 2020
DO  - 10.1016/j.eururo.2020.08.011
UR  - http://hdl.handle.net/10668/16238
T2  - European urology
AB  - The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, apalutamide improved median...
LA  - en
KW  - Apalutamide
KW  - Nonmetastatic castration-resistant prostate cancer
KW  - Overall survival
KW  - Subsequent therapy
KW  - Time to cytotoxic chemotherapy
KW  - Aged
KW  - Cross-Over Studies
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Survival Rate
KW  - Thiohydantoins
TI  - Apalutamide and Overall Survival in Prostate Cancer.
TY  - research article
VL  - 79
ER  -